40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-438.75%
Both yoy net incomes decline, with VET at -8.39%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-11.24%
Negative yoy D&A while VET is 22.22%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
147.62%
Some yoy growth while VET is negative at -64.93%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
154.17%
SBC growth while VET is negative at -12.70%. John Neff would see competitor possibly controlling share issuance more tightly.
-21400.00%
Negative yoy working capital usage while VET is 185.23%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
-100.00%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21400.00%
Negative yoy usage while VET is 0.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-101.55%
Negative yoy while VET is 141.80%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-52.86%
Negative yoy CFO while VET is 90.89%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
8.33%
Lower CapEx growth vs. VET's 54.88%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
-93.52%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
2206.45%
Purchases growth of 2206.45% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-80.38%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
10.70%
We have some outflow growth while VET is negative at -53.56%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-178.01%
We reduce yoy invests while VET stands at 57.77%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
33.33%
Debt repayment growth of 33.33% while VET is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.